EWTX Edgewise Therapeutics, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$41,40
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$14,2552-Wochen-Tief
$48,5152-Wochen-Hoch
Marktkapitalisierung (MRQ)
$4.46B
P/E
-25.7
EPS
$-1.63
Ihre Abzeichen
52W-Spanne
$14–$49
Analystenbewertung
BUY
Kursziel
$53
P/E
-25.7
ROE
-30.2%
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
EWTX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$41.40
Marktkapitalisierung (MRQ)
$4.46B
P/E
-25.7
EPS
$-1.63
ROE
-30.2%
52W-Spanne
$14–$49
EWTX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
EPS$-1.632020-12-31 → 2025-12-31
Freier Cashflow$-144M2021-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | EWTX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -25.75-Jahres-Durchschnitt ≈-12.2 | ≈-12.2 | · | · | |
| K/B (MRQ) | 10.05-Jahres-Durchschnitt ≈3.5 | ≈3.5 | 6.5 | Überbewertet | |
| Kurs / FCF (TTM) | -28.15-Jahres-Durchschnitt ≈-16.2 | ≈-16.2 | · | · | |
| Kurs / Cashflow (TTM) | -28.25-Jahres-Durchschnitt ≈-16.7 | ≈-16.7 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 8.55-Jahres-Durchschnitt ≈3.5 | ≈3.5 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | EWTX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| ROA | -32.3%5-Jahres-Durchschnitt ≈-26.9% | ≈-26.9% | -20.0% | Schwach | |
| ROE | -30.2%5-Jahres-Durchschnitt ≈-25.1% | ≈-25.1% | -20.8% | Schwach | |
| ROIC | -36.6% | · | -17.6% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | EWTX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 16.25-Jahres-Durchschnitt ≈21.6 | ≈21.6 | 11.6 | Starke Liquidität | |
| Quick Ratio | 2.25-Jahres-Durchschnitt ≈2.4 | ≈2.4 | 5.0 | Geringe Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
2.7%
Nächster Bericht
Nov 04, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 6, 2026 | $-0.53 | $-0.48 | -10.6% |
| 31. März 2026 | Mai 7, 2026 | $-0.46 | $-0.50 | 7.3% |
| 31. Dezember 2025 | $-0.47 | $-0.44 | -5.7% | |
| 30. September 2025 | $-0.39 | $-0.41 | 3.8% | |
| 30. Juni 2025 | $-0.34 | $-0.42 | 19.8% | |
| 31. März 2025 | $-0.43 | $-0.44 | 1.7% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $151M | $127M | $91M | $54M | $32M | $15M | |
| SG&A Expense | $40M | $32M | $23M | $18M | $11M | $2M | |
| Operating Expenses | $191M | $159M | $114M | $72M | $43M | $17M | |
| Operating Income | $-191M | $-159M | $-114M | $-72M | $-43M | $-17M | |
| Pretax Income | $-168M | $-134M | $-100M | · | · | · | |
| Income Tax | $4.0K | $3.0K | $4.0K | $0 | $0 | · | |
| Net Income | $-168M | $-134M | $-100M | $-68M | $-43M | $-17M | |
| EPS (Basic) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 | $-23.17 | |
| EPS (Diluted) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 | $-23.17 | |
| Shares (Basic) | 102,930,744 | 92,414,626 | 63,723,600 | 53,593,753 | 37,526,332 | 739,004 | |
| Shares (Diluted) | 102,930,744 | 92,414,626 | 63,723,600 | 53,593,753 | 37,526,332 | 739,004 | |
| EBITDA | $-191M | $-159M | $-114M | $-72M | $-43M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61M | $42M | $86M | $22M | $16M | $105M | |
| Prepaid Expense | $13M | $5M | $9M | $5M | $3M | $551.0K | |
| Current Assets | $543M | $475M | $327M | $357M | $284M | $130M | |
| PP&E (Net) | $8M | $10M | $10M | $9M | $912.0K | $516.0K | |
| PP&E (Gross) | $15M | $14M | $13M | $10M | $2M | $946.0K | |
| Accum. Depreciation | $7M | $5M | $3M | $1M | $702.0K | $430.0K | |
| Other Non-current Assets | · | $262.0K | $348.0K | $251.0K | $548.0K | $975.0K | |
| Total Assets | $553M | $487M | $340M | $367M | $285M | $131M | |
| Accounts Payable | $6M | $6M | $4M | $6M | $4M | $2M | |
| Accrued Liabilities | $8M | $7M | $6M | $6M | $4M | $2M | |
| Current Liabilities | $27M | $24M | $17M | $17M | $11M | $4M | |
| Capital Leases | $3M | $4M | $4M | $4M | · | · | |
| Other Non-current Liabilities | · | · | · | · | $329.0K | · | |
| Total Liabilities | $30M | $28M | $21M | $20M | $11M | $4M | |
| Common Stock | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | · | |
| Paid-in Capital | $1.07B | $837M | $563M | $493M | $352M | $727.0K | |
| Retained Earnings | $-546M | $-379M | $-245M | $-145M | $-77M | $-34M | |
| AOCI | $677.0K | $420.0K | $99.0K | $-1M | $-514.0K | · | |
| Stockholders' Equity | $522M | $459M | $319M | $347M | $274M | $-33M | |
| Liabilities + Equity | $553M | $487M | $340M | $367M | $285M | $131M | |
| Shares Outstanding | 106,249,579 | 94,838,466 | 70,453,342 | 63,257,376 | 49,500,308 | 1,009,479 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $35M | $25M | $18M | $11M | $4M | $354.0K | |
| Operating Cash Flow | $-144M | $-109M | $-92M | $-53M | $-34M | $-15M | |
| CapEx | $256.0K | $1M | $6M | $6M | $668.0K | $203.0K | |
| Investing Cash Flow | $-33M | $-185M | $103M | $-71M | $-242M | $-24M | |
| Stock Issued | $187M | $239M | $53M | $129M | · | · | |
| Net Stock Activity | $187M | $239M | $53M | $129M | · | · | |
| Financing Cash Flow | $196M | $249M | $53M | $130M | $186M | $120M | |
| Net Change in Cash | $19M | $-44M | $64M | $6M | $-89M | $81M | |
| Free Cash Flow | $-144M | $-110M | $-98M | $-58M | $-34M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -32.3% | -32.4% | -28.3% | -20.7% | -20.6% | · | |
| ROE | -30.2% | -28.2% | -32.9% | -19.1% | -15.3% | · | |
| ROIC | -36.6% | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 19.9 | 19.9 | 19.5 | 21.5 | 27.0 | · | |
| Quick Ratio | 2.2 | 1.7 | 5.1 | 1.3 | 1.5 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.92 | $4.84 | $4.53 | $5.48 | $5.54 | · | |
| Cash Flow / Share | $-1.40 | $-1.18 | $-1.44 | $-0.98 | $-0.89 | · | |
| Cash / Share | $0.58 | $0.44 | $1.22 | $0.35 | $0.31 | · | |
| EPS (TTM) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-168M | $-134M | $-100M | $-68M | $-43M | · | |
| Market Cap | $2.64B | $2.53B | $771M | $566M | $756M | · | |
| P/E | -15.2 | -18.4 | -7.0 | -7.1 | -13.4 | · | |
| P/B | 5.0 | 5.5 | 2.4 | 1.6 | 2.8 | · | |
| P / Tangible Book | 5.0 | 5.5 | 2.4 | 1.6 | 2.8 | · | |
| P / Cash Flow | -18.3 | -23.2 | -8.4 | -10.7 | -22.6 | · | |
| P / FCF | -18.3 | -22.9 | -7.9 | -9.7 | -22.1 | · | |
| Earnings Yield | -6.6% | -5.4% | -14.3% | -14.1% | -7.5% | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $48M | $43M | $44M | $37M | $34M | $37M | $36M | $32M | $31M | $28M | $24M | $20M | $20M | $17M | $14M | $12M | |
| SG&A Expense | $14M | $11M | $12M | $9M | $9M | $9M | $9M | $8M | $7M | $7M | $6M | $6M | $6M | $5M | $4M | $4M | |
| Operating Expenses | $62M | $54M | $56M | $47M | $43M | $46M | $46M | $40M | $38M | $35M | $29M | $25M | $26M | $22M | $18M | $16M | |
| Operating Income | $-62M | $-54M | $-56M | $-47M | $-43M | $-46M | $-46M | $-40M | $-38M | $-35M | $-29M | $-25M | $-26M | $-22M | $-18M | $-16M | |
| Net Income | $-57M | $-49M | $-50M | $-41M | $-36M | $-41M | $-40M | $-34M | $-31M | $-29M | $-26M | $-21M | $-23M | $-19M | $-17M | $-16M | |
| EPS (Basic) | $-0.53 | $-0.46 | $-0.47 | $-0.39 | $-0.34 | $-0.43 | $-0.42 | $-0.36 | $-0.34 | $-0.33 | $-0.41 | $-0.34 | $-0.36 | $-0.30 | $-0.34 | $-0.32 | |
| EPS (Diluted) | $-0.53 | $-0.46 | $-0.47 | $-0.39 | $-0.34 | $-0.43 | $-0.42 | $-0.36 | $-0.34 | $-0.33 | $-0.41 | $-0.34 | $-0.36 | $-0.30 | $-0.34 | $-0.32 | |
| Shares (Basic) | 107,669,774 | 107,116,709 | · | 105,492,779 | 104,940,493 | 95,130,053 | · | 93,813,346 | 93,515,356 | 87,567,307 | 63,459,560 | 63,380,430 | 63,265,800 | · | 51,844,904 | 49,622,752 | |
| Shares (Diluted) | 107,669,774 | 107,116,709 | · | 105,492,779 | 104,940,493 | 95,130,053 | · | 93,813,346 | 93,515,356 | 87,567,307 | 63,459,560 | 63,380,430 | 63,265,800 | · | 51,844,904 | 49,622,752 | |
| EBITDA | $-62M | $-54M | · | $-47M | $-43M | $-46M | · | $-40M | $-38M | $-35M | $-29M | $-25M | $-26M | · | $-18M | $-16M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $33M | $61M | $46M | $43M | $50M | $42M | $45M | $43M | $30M | $33M | $32M | $48M | $22M | $110M | $18M | |
| Prepaid Expense | $6M | $10M | $13M | $11M | $9M | $7M | $5M | $7M | $8M | $9M | $8M | $7M | $5M | $5M | $5M | $5M | |
| Current Assets | $472M | $510M | $543M | $574M | $603M | $443M | $475M | $499M | $519M | $541M | $298M | $317M | $333M | $357M | $370M | $253M | |
| PP&E (Net) | $7M | $7M | $8M | $8M | $9M | $9M | $10M | $10M | $10M | $10M | $11M | $11M | $10M | $9M | $5M | $2M | |
| PP&E (Gross) | $15M | $15M | $15M | $14M | $14M | $14M | $14M | $14M | $13M | $13M | $13M | $13M | $12M | $10M | $6M | $3M | |
| Accum. Depreciation | $8M | $7M | $7M | $6M | $6M | $5M | $5M | $4M | $4M | $3M | $2M | $2M | $1M | $1M | $977.0K | $882.0K | |
| Other Non-current Assets | · | · | · | · | · | $695.0K | $262.0K | $262.0K | $262.0K | · | $467.0K | $419.0K | $251.0K | $251.0K | $264.0K | $447.0K | |
| Total Assets | $480M | $519M | $553M | $583M | $613M | $454M | $487M | $511M | $532M | $554M | $311M | $331M | $346M | $367M | $377M | $257M | |
| Accounts Payable | $5M | $7M | $6M | $6M | $8M | $9M | $6M | $6M | $7M | $5M | $5M | $4M | $4M | $6M | $6M | $3M | |
| Accrued Liabilities | $5M | $9M | $8M | $6M | $6M | $7M | $7M | $6M | $5M | $6M | $6M | $7M | $6M | $6M | $5M | $4M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7.0K | · | |
| Current Liabilities | $29M | $23M | $27M | $22M | $21M | $21M | $24M | $19M | $17M | $15M | $16M | $14M | $13M | $17M | $13M | $9M | |
| Capital Leases | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | $2M | $2M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $192.0K | |
| Total Liabilities | $32M | $25M | $30M | $25M | $24M | $25M | $28M | $22M | $21M | $19M | $21M | $19M | $18M | $20M | $16M | $11M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $59.0K | · | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7.0K | · | |
| Common Stock | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | |
| Paid-in Capital | $1.10B | $1.09B | $1.07B | $1.05B | $1.04B | $849M | $837M | $827M | $816M | $809M | $505M | $501M | $497M | $493M | $489M | $356M | |
| Retained Earnings | $-653M | $-595M | $-546M | $-496M | $-455M | $-419M | $-379M | $-339M | $-305M | $-273M | $-215M | $-189M | $-167M | $-145M | $-125M | $-108M | |
| AOCI | $-500.0K | $-252.0K | $677.0K | $701.0K | $204.0K | $401.0K | $420.0K | $1M | $-1M | $-861.0K | $-424.0K | $-547.0K | $-251.0K | $-1M | $-2M | $-2M | |
| Stockholders' Equity | $448M | $493M | $522M | $559M | $589M | $430M | $459M | $489M | $510M | $535M | $290M | $311M | $329M | $347M | $361M | $246M | |
| Liabilities + Equity | $480M | $519M | $553M | $583M | $613M | $454M | $487M | $511M | $532M | $554M | $311M | $331M | $346M | $367M | $377M | $257M | |
| Shares Outstanding | 107,776,380 | 107,481,522 | 106,249,579 | 105,761,949 | 105,341,296 | 95,205,683 | 94,838,466 | 94,408,911 | 93,643,341 | 93,284,528 | 63,460,939 | 63,458,932 | 63,274,732 | 63,257,376 | 63,208,828 | 49,780,365 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $9M | $9M | $10M | $8M | $8M | $9M | $8M | $7M | $5M | $5M | $5M | $4M | $4M | $4M | $3M | $2M | |
| Operating Cash Flow | $-42M | $-43M | $-39M | $-35M | $-33M | $-38M | $-27M | $-27M | $-26M | $-29M | $-22M | $-20M | $-23M | $-12M | $-12M | $-16M | |
| CapEx | $32.0K | $260.0K | $73.0K | $89.0K | $50.0K | $44.0K | $274.0K | $520.0K | $221.0K | $297.0K | $457.0K | $759.0K | $4M | $3M | $1M | $554.0K | |
| Investing Cash Flow | $78M | $2M | $50M | $36M | $-162M | $44M | $21M | $25M | $37M | $-268M | $23M | $3M | $49M | $-76M | $-26M | $-46.0K | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | $0 | $239M | · | · | · | $-555.0K | · | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $239M | · | · | · | · | · | · | |
| Financing Cash Flow | $3M | $12M | $4M | $2M | $188M | $2M | $3M | $3M | $2M | $241M | $-211.0K | $369.0K | $21.0K | $-303.0K | $130M | $179.0K | |
| Net Change in Cash | $39M | $-28M | $15M | $3M | $-7M | $8M | $-3M | $1M | $13M | $-56M | $1M | $-16M | $26M | $-88M | $91M | $-16M | |
| Free Cash Flow | · | $-43M | · | · | · | · | · | · | · | $-29M | · | · | $-27M | · | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -10.5% | -10.1% | · | -7.4% | -6.3% | -8.1% | · | -8.3% | -7.3% | -6.3% | -7.5% | -7.3% | -7.4% | · | -5.2% | -5.7% | |
| ROE | -11.1% | -10.6% | · | -7.8% | -6.6% | -8.5% | · | -8.8% | -7.7% | -6.6% | -7.9% | -7.7% | -7.8% | · | -5.4% | -5.9% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 16.2 | 22.6 | · | 26.5 | 28.9 | 21.0 | · | 26.3 | 30.2 | 37.1 | 18.2 | 22.0 | 26.2 | · | 27.8 | 27.5 | |
| Quick Ratio | 2.5 | 1.5 | · | 2.1 | 2.1 | 2.4 | · | 2.4 | 2.5 | 2.1 | 2.0 | 2.2 | 3.8 | · | 8.2 | 2.0 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.16 | $4.59 | · | $5.28 | $5.59 | $4.51 | · | $5.18 | $5.45 | $5.73 | $4.58 | $4.91 | $5.20 | · | $5.72 | $4.95 | |
| Cash Flow / Share | · | $-0.40 | · | · | · | $-0.40 | · | · | · | $-0.33 | · | · | $-0.36 | · | · | · | |
| Cash / Share | $0.67 | $0.31 | · | $0.43 | $0.41 | $0.52 | · | $0.47 | $0.46 | $0.32 | $0.52 | $0.50 | $0.76 | · | $1.74 | $0.37 | |
| EPS (TTM) | $-1.85 | $-1.66 | · | $-1.58 | $-1.55 | $-1.55 | · | $-1.49 | $-1.54 | $-1.54 | $-1.41 | $-1.34 | $-1.32 | · | $2.74 | $2.82 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-197M | $-176M | · | $-157M | $-151M | $-146M | · | $-124M | $-116M | $-106M | $-89M | $-81M | $-76M | · | $-61M | $-56M | |
| Market Cap | $4.38B | $3.39B | · | $1.72B | $1.38B | $2.09B | · | $2.52B | $1.69B | $1.70B | $364M | $492M | $422M | · | $622M | $396M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $512M | · | |
| P/E | -22.0 | -19.0 | · | -10.3 | -8.5 | -14.2 | · | -17.9 | -11.7 | -11.8 | -4.1 | -5.8 | -5.1 | · | 3.6 | 2.8 | |
| P/B | 9.8 | 6.9 | · | 3.1 | 2.3 | 4.9 | · | 5.2 | 3.3 | 3.2 | 1.3 | 1.6 | 1.3 | · | 1.7 | 1.6 | |
| P / Tangible Book | 9.8 | 6.9 | · | 3.1 | 2.3 | 4.9 | · | 5.2 | 3.3 | 3.2 | 1.3 | 1.6 | 1.3 | · | 1.7 | 1.6 | |
| P / Cash Flow | · | -79.6 | · | · | · | -55.3 | · | · | · | -59.5 | · | · | -18.5 | · | · | · | |
| Earnings Yield | -4.5% | -5.3% | · | -9.7% | -11.8% | -7.0% | · | -5.6% | -8.6% | -8.4% | -24.6% | -17.3% | -19.8% | · | 27.9% | 35.4% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Nettoergebnis | $-168M | $-134M | $-100M | $-68M | $-43M |
| Verwässerte EPS | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 19.9 | 19.9 | 19.5 | 21.5 | 27.0 |
| Quick Ratio | 2.2 | 1.7 | 5.1 | 1.3 | 1.5 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-144M | $-110M | $-98M | $-58M | $-34M |
Institutionelle Eigentümer (13F) 247 Einreicher · $4.9B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
247
Gehaltener Wert
$4.9B
Neue Positionen
41
Geschlossene Positionen
25
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 41 (-11 vs. Vorquartal) | 25 (+2 vs. Vorquartal) | 85 (+18 vs. Vorquartal) | 76 (+8 vs. Vorquartal) | -5.6M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | $630.516.330 | 15.518.492 | 12,91% | Aktien |
| Paradigm Biocapital Advisors LP | $415.053.937 | 10.215.455 | 8,50% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $340.996.620 | 8.392.730 | 6,98% | Aktien |
| BlackRock, Inc. | $268.415.431 | 6.606.336 | 5,50% | Aktien |
| FMR LLC | $223.023.556 | 5.489.135 | 4,57% | Aktien |
| NOVO HOLDINGS A/S | $217.370.500 | 5.350.000 | 4,45% | Aktien |
| Driehaus Capital Management LLC | $192.123.952 | 4.728.623 | 3,94% | Aktien |
| JANUS HENDERSON GROUP PLC | $186.289.082 | 5.915.556 | 3,82% | Aktien |
| PERCEPTIVE ADVISORS LLC | $177.714.564 | 4.373.974 | 3,64% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $156.859.022 | 3.860.670 | 3,21% | Aktien |
| BAKER BROS. ADVISORS LP | $150.400.843 | 3.701.719 | 3,08% | Aktien |
| Siren, L.L.C. | $129.391.476 | 3.184.629 | 2,65% | Aktien |
| VANGUARD GROUP INC | $120.889.349 | 4.871.624 | 2,48% | Aktien |
| Cormorant Asset Management, LP | $101.981.300 | 2.510.000 | 2,09% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $88.348.054 | 2.174.051 | 1,81% | Aktien |
| Integral Health Asset Management, LLC | $81.260.000 | 2.000.000 | 1,66% | Aktien |
| BRAIDWELL LP | $81.136.688 | 1.996.965 | 1,66% | Aktien |
| MORGAN STANLEY | $79.171.495 | 1.948.597 | 1,62% | Aktien |
| STATE STREET CORP | $74.268.674 | 1.827.927 | 1,52% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $66.749.256 | 2.119.024 | 1,37% | Aktien |
| MPM BIOIMPACT LLC | $65.852.291 | 1.620.780 | 1,35% | Aktien |
| BANK OF AMERICA CORP /DE/ | $63.312.105 | 1.558.260 | 1,30% | Aktien |
| Qube Research & Technologies Ltd | $50.889.359 | 1.252.507 | 1,04% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $46.309.097 | 1.139.726 | 0,95% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $45.793.233 | 1.127.078 | 0,94% | Aktien |
| First Light Asset Management, LLC | $44.496.798 | 1.095.171 | 0,91% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $36.683.608 | 902.870 | 0,75% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31.953.707 | 786.456 | 0,65% | Aktien |
| NORTHERN TRUST CORP | $27.273.701 | 671.270 | 0,56% | Aktien |
| Aberdeen Group plc | $26.325.233 | 647.926 | 0,54% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $25.212.215 | 620.532 | 0,52% | Aktien |
| Tyro Capital Management LLC | $24.904.768 | 612.965 | 0,51% | Aktien |
| GOLDMAN SACHS GROUP INC | $24.356.425 | 599.469 | 0,50% | Aktien |
| Parkman Healthcare Partners LLC | $23.444.973 | 577.036 | 0,48% | Aktien |
| Artisan Partners Limited Partnership | $23.359.203 | 574.925 | 0,48% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $22.276.820 | 548.285 | 0,46% | Aktien |
| NORGES BANK | $20.726.988 | 510.140 | 0,42% | Aktien |
| Opaleye Management Inc. | $20.315.000 | 500.000 | 0,42% | Aktien |
| CITADEL ADVISORS LLC | $19.084.196 | 469.707 | 0,39% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $18.771.060 | 462.000 | 0,38% | Aktien |
| Soleus Capital Management, L.P. | $18.319.620 | 450.889 | 0,38% | Aktien |
| Nuveen, LLC | $16.849.506 | 414.706 | 0,35% | Aktien |
| New Leaf Venture Partners, L.L.C. | $16.709.211 | 1.030.161 | 0,34% | Aktien |
| Sofinnova Investments, Inc. | $15.476.901 | 380.923 | 0,32% | Aktien |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $13.570.989 | 334.014 | 0,28% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $12.902.666 | 317.565 | 0,26% | Aktien |
| Squadron Capital Management LLC | $11.782.700 | 290.000 | 0,24% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $11.511.820 | 283.333 | 0,24% | Aktien |
| DIADEMA PARTNERS LP | $11.060.055 | 272.214 | 0,23% | Aktien |
| PRUDENTIAL FINANCIAL INC | $10.593.257 | 260.725 | 0,22% | Aktien |
Aktivisten & 5%+-Eigentümer 3 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Novo Holdings A/S ×7 Einreichungen | 27. April 2026 | 4,90% | Änderung | · | SEC |
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VI LLC, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC ×5 Einreichungen | 12. Mai 2025 | 14,50% | Änderung | · | SEC |
| U.S. Venture Partners XI, L.P. (“USVP XI”), Presidio Management Group XI, L.L.C. (“PMG XI”), Casey M. Tansey, Jonathan D. Root ×2 Einreichungen | 1. Februar 2023 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 18 Insider · 7 Führungskräfte · 8 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Michael Nofi | Chief Financial Officer | 12. August 2026 A | · | 0 | 0 | $0 |
| Michael R Carruthers | Chief Financial Officer | 12. August 2025 A | 86.162 | 0 | 0 | $0 |
| Alan J Russell | Chief Scientific Officer | 12. August 2026 A | 31.466 | 0 | 6 | $-10.252.060 |
| Behrad Derakhshan | Chief Business Officer | 12. August 2026 A | 31.826 | 0 | 4 | $-223.420 |
| Joanne M. Donovan | CMO | 12. August 2026 A | 8.625 | 0 | 11 | $-4.623.076 |
| Robert Blaustein | Chief Development Officer | 12. August 2025 A | · | 0 | 0 | $0 |
| Marc Semigran | Chief Development Officer | 24. Dezember 2024 M | 6.716 | 0 | 0 | $0 |
| Jonathan C Fox | Direktor | 1. Oktober 2026 A | 25.141 | 1 | 0 | $199.448 |
| Christopher Nathan Martin | Direktor | 5. Juni 2026 A | · | 0 | 0 | $0 |
| Badreddin Edris | Direktor | 5. Juni 2026 A | 19.820 | 0 | 5 | $-3.399.467 |
| Laura Brege | Direktor | 5. Juni 2026 A | · | 0 | 0 | $0 |
| Arlene Morris | Direktor | 5. Juni 2026 A | · | 0 | 0 | $0 |
| Peter A. Thompson | Direktor | 5. Juni 2026 A | 443.792 | 0 | 0 | $0 |
| Jonathan D Root | Direktor | 5. Juni 2026 A | 0 | 0 | 0 | $0 |
| Novo Holdings A/S | 10%-Eigentümer | 14. September 2022 P | 6.071.703 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10%-Eigentümer | 30. März 2021 C | 681.812 | 0 | 0 | $0 |
| John R Moore | · | 12. August 2026 A | 17.697 | 0 | 4 | $-219.831 |
| Kevin Koch | · | 12. August 2026 A | 52.488 | 0 | 3 | $-785.049 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 35 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,53% | 6.153 SH | 11. September 2026 | Täglich |
| PTH · Invesco Exchange-Traded Fund Trust | 1,36% | 96.973 SH | 2. Oktober 2026 | Täglich |
| PILL · Direxion Shares ETF Trust | 1,33% | 7.137 NS | 31. Juli 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,74% | 8.925 NS | 31. Juli 2026 | N-PORT |
| IHE · iShares Trust | 0,74% | 278.770 SH | 11. September 2026 | Täglich |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,35% | 35.134 SH | 2. Oktober 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,29% | 7.672 SH | 2. Oktober 2026 | Täglich |
| IBB · iShares Trust | 0,25% | 599.006 SH | 11. September 2026 | Täglich |
| IWO · iShares Trust | 0,20% | 671.171 SH | 11. September 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,17% | 76.681 SH | 19. August 2026 | Täglich |
| VFMO · VANGUARD WELLINGTON FUND | 0,13% | 65.171 SH | 19. August 2026 | Täglich |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,13% | 23.462 NS | 31. Juli 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,11% | 2.494 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,10% | 1.832.689 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,09% | 411.642 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,09% | 34.242 NS | 31. Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,06% | 14.090 SH | 10. September 2026 | Täglich |
| ESML · iShares Trust | 0,05% | 33.329 SH | 11. September 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,04% | 168.775 NS | 31. Juli 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,04% | 24.755 SH | 2. Oktober 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 864.416 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,03% | 145.298 SH | 19. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 22.934 NS | 31. Juli 2026 | N-PORT |
| WSML · iShares Trust | 0,02% | 3.133 SH | 9. September 2026 | Täglich |
| TILT · FlexShares Trust | 0,01% | 6.190 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2.902.915 SH | 19. August 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,01% | 103.617 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 5.796 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 105.809 SH | 11. September 2026 | Täglich |
| DFAU · Dimensional ETF Trust | 0,00% | 15.310 NS | 31. Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 21.128 SH | 10. September 2026 | Täglich |
| DFUS · Dimensional ETF Trust | 0,00% | 9.509 NS | 31. Juli 2026 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 5.890 SH | 19. August 2026 | Täglich |
| ISCB · iShares Trust | · | 3.892 SH | 11. September 2026 | Täglich |
| ISCV · iShares Trust | · | 9.439 SH | 11. September 2026 | Täglich |
EWTX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 19 Analysten
KAUF
Median-Ziel
$53.00
+28,0%
7 36,8%
Starker Kauf
9 47,4%
Kauf
3 15,8%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
13 Analysten · 2026-09-29Mittelwert-Ziel $52.62 +27,1%
Jetzt
Aktueller Preis $41.40
Tief$36.00
Mittelwert$52.62
Hoch$66.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| EWTX | $2.64B | -15.2 | · | · | -30.2% | · |
| AMRX | · | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | · |
| DFTX | $1.32B | -6.5 | 212.0% | · | -71.0% | · |
| MANE | · | · | · | · | 82.6% | · |
| INDV | · | 21.9 | 4.3% | 17.0% | -118.3% | 80.2% |
| OGN | $1.87B | 10.0 | -2.9% | 3.0% | 25.2% | 53.3% |
| AMLX | $1.33B | -7.9 | -77.1% | · | -61.2% | · |
| TARS | $3.48B | -51.5 | 146.7% | -14.7% | -19.7% | · |
| ELVN | $915M | -8.4 | · | · | -21.9% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026